Tuesday, December 19, 2017 3:41:43 PM
This stock was expected to be about $15 right now when the details of the Novartis deal were announced a year ago.
Since then, nothing bad has happened (except the small secondary) and all remains well. Yes, the 4 Ph2 trials did get pushed out a tiny amount (about 2 or 3 months) but for that the stock was wwwaaaayyyy overly punished.
CNAT is now only a few months away from the first results trickling in.
CNAT has now likely got tax loss selling behind it.
CNAT short interest is about 1.6mil shares - a significant number.
Look what mdgl did a week or two ago. CNAT will go up $30 in a single day if the first results are encouraging.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM